FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Deem Roll Tech IPO and Zenith Drugs IPO.
Deem Roll Tech IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Zenith Drugs IPO is a SME Book Built Issue proposed to list at NSE SME.
Deem Roll Tech IPO | Zenith Drugs IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Fixed Price Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Fedex Securities Pvt Ltd | Gretex Corporate Services Limited |
Registrar | Bigshare Services Pvt Ltd | Bigshare Services Pvt Ltd |
Market Maker | Ss Corporate Securities Limited | Gretex Share Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Deem Roll Tech IPO is up to ₹29.26 Cr whereas the issue size of the Zenith Drugs IPO is up to ₹40.68 Cr. The final issue price of Deem Roll Tech IPO is ₹129.00 per share and of Zenith Drugs IPO is ₹79.00 per share.
Deem Roll Tech IPO | Zenith Drugs IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹75.00 per share | |
Issue Price (Upper) | ₹79.00 per share | |
Issue Price (Final) | ₹129.00 per share | ₹79.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 1000 shares | 1600 shares |
Fresh Issue Size | 22,68,000 shares | 51,48,800 shares |
Fresh Issue Size (Amount) | up to ₹29.26 Cr | up to ₹40.68 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 22,68,000 shares | 51,48,800 shares |
Issue Size Total (Amount) | up to ₹29.26 Cr | up to ₹40.68 Cr |
Deem Roll Tech IPO opens on Feb 20, 2024, while Zenith Drugs IPO opens on Feb 19, 2024. The closing date of Deem Roll Tech IPO and Zenith Drugs IPO is Feb 22, 2024, and Feb 22, 2024, respectively.
Deem Roll Tech IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Bid Date | Feb 16, 2024 | |
Issue Open | Feb 20, 2024 | Feb 19, 2024 |
Issue Close | Feb 22, 2024 | Feb 22, 2024 |
Basis Of Allotment (Tentative) | Feb 23, 2024 | Feb 23, 2024 |
Initiation of Refunds (Tentative) | Feb 26, 2024 | Feb 26, 2024 |
Credit of Share (Tentative) | Feb 26, 2024 | Feb 26, 2024 |
Listing date (Tentative) | Feb 27, 2024 | Feb 27, 2024 |
Anchor Lockin End date 1 | Mar 24, 2024 | |
Anchor Lockin End date 2 | May 23, 2024 |
Deem Roll Tech IPO P/E ratio is 11.31, as compared to Zenith Drugs IPO P/E ratio of 18.4.
Deem Roll Tech IPO | Zenith Drugs IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Deem Roll Tech Limited Financial Information (Restated)Deem Roll Tech Limited's revenue increased by 13.42% and profit after tax (PAT) rose by 68.88% between the financial year ending with March 31, 2023 and March 31, 2022.
|
Zenith Drugs Limited Financial Information (Restated Consolidated)Zenith Drugs Limited's revenue increased by 24.85% and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023 and March 31, 2022.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 92.18% | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 67.12% | 69.98% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 11.31 | 18.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹107.55 Cr. | ₹135.48 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 16.83%% | 35.13%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 20.26%% | 37.29%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.47 | 1.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹11.40 | ₹4.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 20.31%% | 29.88%% |
In the Deem Roll Tech IPO retail investors (RII) are offered 10,77,000 shares while in Zenith Drugs IPO retail investors are offered 10,77,000 shares. Qualified institutional buyers (QIB) are offered 0 shares in Deem Roll Tech IPO and 8,59,200 shares in Zenith Drugs IPO.
Deem Roll Tech IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Investor Reserveration | 12,88,000 shares | |
Market Maker Reserveration | 1,14,000 shares | 8,52,800 shares |
QIB | 0 shares | 8,59,200 shares |
NII | 10,77,000 shares | 6,44,800 shares |
RII | 10,77,000 shares | 15,04,000 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 21,54,000 shares | 30,08,000 shares |
Deem Roll Tech IPO subscribed 256.55x in total, whereas Zenith Drugs IPO subscribed 179.18x.
Deem Roll Tech IPO | Zenith Drugs IPO | |
---|---|---|
QIB (times) | 106.72x | |
NII (times) | 311.95x | 368.77x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 180.50x | 139.28x |
Employee (times) | ||
Other (times) | ||
Total (times) | 256.55x | 179.18x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|